Tag: MSD

Sutro Biopharma entered into collaboration with MSD

biotech
Sutro Biopharma has signed a collaboration and licensing agreement with MSD (known as Merck in USA and Canada), to discover and develop novel immune-modulating therapies for cancer and autoimmune disorders.

WHO employs experimental Ebola vaccine for the ongoing outbreak in Congo

ebola-vaccine
In response to the ongoing outbreak of Ebola in Democratic Republic of the Congo, WHO with The Government of the Democratic Republic of Congo preparing to vaccinate high risk populations against Ebola virus disease.

MSD and Moderna Therapeutics will develop novel cancer vaccines

merck
Merck, known as MSD outside the United States and Canada, and Moderna Therapeutics announced a strategic collaboration and license agreement to develop and commercialize novel messenger RNA-based personalized cancer vaccines.

MSD start clinical studies of its investigational polyvalent conjugate vaccine

merck
MSD (known as "Merck" in USA and Canada) announced that the company is beginning two Phase 3 studies of PCV-15 (V114), its investigational polyvalent conjugate vaccine for the prevention of pneumococcal disease.

Immutep starts a clinical trial collaboration with MSD

biotechnologies
Immutep, a leading Australian biotechnology company, announced that it has entered into a clinical trial collaboration and supply agreement with MSD to evaluate the combination of Immutep’s lead immunotherapy product

Samsung Bioepis biosimilar cancer drug begun to sell in Europe

biosimilars
Korean biopharmaceutical firm Samsung Bioepis informed that its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator (EMA).

Eisai and MSD will jointly develop and commercialize a thyroid cancer therapy

cancer-diagnostics
Eisai Co., Ltd. and MSD agreed upon a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA (lenvatinib mesylate), an orally available tyrosine kinase inhibitor discovered by Eisai.

MSD and AKRIKHIN localized manufacturing of sitagliptin in Russia

akrikhin
MSD, an innovative global pharmaceutical company, and AKRIKHIN, a leading Russian pharmaceutical manufacturer, announced the successful localization of 100 mg finished dosage form of sitagliptin.

Ferring and MSD completed the Carbetocin Haemorrhage Prevention clinical trial

ferring
Ferring Pharmaceuticals and MSD announced the completion of CHAMPION (Carbetocin Haemorrhage Prevention), a global clinical trial conducted by the Human Reproduction Program at the World Health Organization.

MSD acquires an Australian biotechnology company

merck
Merck and Viralytics Limited announced that the companies have signed a definitive agreement under which Merck will acquire Viralytics, an Australian company focused on oncolytic immunotherapy treatments for a range of cancers.

GlobalData expects that Merck will set to lead licensing deals in 2018

merck
Companies’ financial success is often down to the strategic deals they are able to make with other pharmaceutical companies to enable them to develop the next leading drug in the market, observes GlobalData

MSD considers the possibility of localizing the vaccines manufacturing in Russia

research
According to Marwan Akar, MSD Director General in Russia, Kazakhstan and Belarus, the company is exploring the possibility of localizing in Russia the manufacturing of vaccines

N.A. Semashko National Research Institute and MSD announce their collaboration

handshake
N.A. Semashko National Research Institute of Public Health and MSD announced that they begin to collaborate

Pembrolizumab is included in Russian List of Vital and Essential Drugs for 2018

msd
Pembrolizumab, an immuno-oncological medicine, is included in the approved List of Vital and Essential Drugs for 2018.

Merck will buy Rigontec to firm up its leadership in immuno-oncology

merck
Merck, known as MSD, and Rigontec today announced that Merck will acquire Rigontec

AstraZeneca and Merck started oncology collaboration

astrazeneca
AstraZeneca and Merck & Co., Inc., known as MSD outside of the United States and Canada, today announced that they have entered a global strategic oncology collaboration